Drug intelligence / Profile preview

SGB-IM03

Development stage: Preclinical
Lead developer: Sanegene Bio
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SGB-IM03 is a small interfering RNA (siRNA) therapeutic candidate developed by Suzhou Shengyin Biopharmaceutical (Sanegene Bio). It is designed to target Macrophage Stimulating 1 (MST1), also known as Hepatocyte Growth Factor-like protein (HGFL), using RNA interference (RNAi) technology. By silencing the expression of MST1 mRNA, the drug aims to modulate inflammatory and fibrotic pathways associated with Chronic Obstructive Pulmonary Disease (COPD) and other potential indications. As of 2024, SGB-IM03 is in the Lead Identification (Lead ID) stage of preclinical development, representing part of Sanegene Bio's pipeline of RNA-based medicines for respiratory and metabolic diseases.

Targets

STK4 (MST1 / STK4)

Beyond the preview

Go deeper on SGB-IM03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGB-IM03.

Explore the full profile